Exploiting the fibroblast growth factor receptor-1 vulnerability to therapeutically restrict the MYC-EZH2-CDKN1C axis-driven proliferation in Mantle cell lymphoma

Anuvrat Sircar(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Lalit Sehgal(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Ken H. Young(Duke Medical Center), Laura K. Hilton(BC Cancer Agency), Neeraj Jain(The University of Texas MD Anderson Cancer Center), Zijun Y. Xu‐Monette(Duke University), Blake R. Peterson(St. Michael's Hospital), Evangelia Chavdoula(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Walter Hanel(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Krysta M. Coyle(Simon Fraser University), Satishkumar Singh(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Lapo Alinari(University of Milan), Jianguo Tao(University of Virginia), Parvathi Ranganathan(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Ryan D. Morin(Simon Fraser University), Narendranath Epperla(University of Utah), Natarajan Muthusamy(Manonmaniam Sundaranar University), Philip N. Tsichlis(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Robert A. Baiocchi(The Ohio State University Wexner Medical Center)
Leukemia
August 19, 2023
10.1038/s41375-023-02006-8
Cited by 13

Related Papers

A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications
|Cancer Cell|2020|1.1k
Metformin Selectively Targets Cancer Stem Cells, and Acts Together with Chemotherapy to Block Tumor Growth and Prolong Remission
|Cancer Research|2009|1.1k
Immunohistochemical Double-Hit Score Is a Strong Predictor of Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
|Journal of Clinical Oncology|2012|682
MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program
|Blood|2013|677
Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas
|Nature Medicine|2020|593